A display contains frozen items, and the shelves are stocked with jars and cans. But there’s just one reason to visit this Boerum Hill business: meat.
NYS Entity Status
NYS Filing Date
DECEMBER 06, 2013
NYS DOS ID#
UNITED STATES CORPORATION AGENTS, INC.
7014 13TH AVENUE, SUITE 202
BROOKLYN, NEW YORK, 11228
NYS Entity Type
DOMESTIC BUSINESS CORPORATION
2013 - GARGANO SALES & MARKETING, INC.
AROUND THE WEB
- Neighborhood Joint: Staubitz Market in Brooklyn: 100 Years of Sawdust, Steaks and Chops
By ANDREW COTTO - Wednesday Jun 14, 2017
- 19th-Century Diary Suggests Slaves Are Buried in Brooklyn Lot
By MICHAEL WILSON - Friday Aug 4, 2017
A Gowanus farmer’s writings from 1828 to 1830 describe burying them on property that includes the proposed site of a prekindergarten.
- Time Inc Taps Schraft To Head Foundry's Content Sales, 'New Yorker' Hires First Newsletter Director
Thursday Jul 13, 2017
In a move to expand its native advertising business, Time Inc. has promoted Chris Schraft to president of content sales and agency development of The Foundry, its branded content studio. 'The NewYorker' has hired Dan Oshinsky as its first director of newsletters.
- We Taste-Tested 10 Hot Dogs. Here Are the Best.
By JULIA MOSKIN - Tuesday Jun 27, 2017
Sam Sifton, Melissa Clark and Julia Moskin tried 10 hot dogs for cookout season.
- Abbvie’s hep C drug pricing threatens Gilead’s dominance
By Max Nisen - Tuesday Aug 8, 2017
Pharma already leads the business world in unpredictability, with billions in sales potentially riding on a few points of statistical significance in a clinical trial.[...] even within that context, a series of blockbuster medicines for hepatitis C have made for a roller-coaster ride for companies and investors.AbbVie Inc. last week threw another big curve at this market by pricing its newly FDA-approved drug Mavyret — which might be the most effective hepatitis C medicine approved yet — at a massive discount.Medicines from Johnson & Johnson, Merck & Co. Inc. and Vertex Pharmaceuticals Inc. approved within the past six years, which once booked billions in combined sales, are now essentially non-factors.After offering behind-the-scene discounts to insurance companies, pharmacy benefit managers and other payers, Mavyret’s price is actually not far from Harvoni’s, according to Bloomberg Intelligence.The real headache for Gilead — which already faces steep declines in hepatitis C drug sales because of increasing competition and the fact that many patients have been cured — lies in the fact that not all hepatitis patients or medicines are the same.AbbVie’s new drug can treat all of the major subtypes of hepatitis C. And it can cure the disease in many patients in just eight weeks.